Does the Inactivated Influenza Vaccine Even Work In the Recommended Age Bracket?
Filed under: News, Parents' Pages, Vaccine Science, Vaccine/Disease Analysis, WHO Watch
It’s that time of year again! Having spent last summer consulting the avian set on what’s hot in influenza, the pharmaceutical company has whipped up a fresh batch of flu vaccine, and now they need to move the merchandise! Fortunately, the CDC is happy to help with sales, by expanding the recommendation to ever more age groups. The Advisory Committee on Immunization Policy currently recommends the vaccine for all children aged 6 months to eighteen years. There is just one slight issue that might concern some parents. Peer-reviewed research in The Archives of Pediatric and Adolescent Medicine, Vol. 162 No. 10, October 2008,1 demonstrates that the vaccine is not effective under age 5!
An inherent assumption of expanded vaccination recommendations is that the vaccine is efficacious in preventing clinical influenza disease. Although studies have documented immune responses following 2 doses of inactivated influenza vaccine as well as vaccine efficacy for culture-confirmed disease in randomized clinical trials, surprisingly little information exists regarding influenza vaccine effectiveness (VE) among young children receiving vaccine in routine health care settings.
Merck staph vaccine enters phase II
From Forbes:
VIENNA, Aug 28 (Reuters) – Austrian biotech firm Intercell <ICEL.VI> said on Thursday its partner Merck & Co <MRK.N> has started a Phase II clinical trial to evaluate a vaccine candidate against Staphylococcus aureus infections.
Merck is responsible for clinical development, manufacturing and marketing of the vaccine. Intercell is eligible to receive milestone payments and royalties on future net sales
This is the second trial start following a separate Phase II trial launch in December 2007. Read more